Short-term efficacy of cetuximab-contained regimen on patients with advanced gastric and esophageal cancer
10.3760/cma.j.issn.1673-422X.2010.03.018
- VernacularTitle:含西妥昔单抗方案治疗胃癌和食管癌的近期疗效
- Author:
Liangping XIA
;
Guifang GUO
- Publication Type:Journal Article
- Keywords:
Cetuximab;
Drug therapy;
Stomach neoplasms;
Esophageal neoplasms
- From:
Journal of International Oncology
2010;37(3):217-219
- CountryChina
- Language:Chinese
-
Abstract:
Few studies of cetuximab on patients with gastric and esophageal cancer were available now.The disease control rate was 72.7%～92%,OS was 9.5～16.6months,PFS/was 6.2～11 months among first-line setting with cetuximab-contained regimens.And cetuximab shown in second-line regimen setting overcome the resistance of irinotecan and docetaxel.The pCR was 13%～65% when cetuximab was used as induction treatment combined with concurrent chemoradiation.18F-FDG-PET was a potential method to predictthe efficacy of cetuximab-contained regimens,however,status of Kras gene had no predictive value.
